Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

USP5 Promotes Ripretinib Resistance in Gastrointestinal Stromal Tumors by MDH2 Deubiquition

8 Jul 2024

Abstract excerpt

Ripretinib, a broad-spectrum inhibitor of the KIT and PDGFRA receptor tyrosine kinases, is designated as a fourth-line treatment for gastrointestinal stromal tumor (GIST). It is tailored for patients resistant to imatinib, sunitinib, and regorafenib. As its increasing use, instances of resistance to ripretinib are becoming more frequent. Unfortunately, there are currently no scientifically mature treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gastrointestinal Tumor Research and Treatment
Share to Neurofibromatosis and Schwannoma Cases
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38973363
DOI: 10.1002/advs.202401171

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

USP5 Promotes Ripretinib Resistance in Gastrointestinal Stromal Tumors by MDH2 DeubiquitionPMID 38973363Read ↗

Spotlights on ubiquitin-specific protease 12 (USP12) in diseases: from multifaceted roles to pathophysiological mechanismsSemantic proximity Read ↗

Deubiquitinase USP9X loss Sensitizes Cancer Cells to mTOR Inhibitors through p62 DysregulationSemantic proximity Read ↗

Cellular functions, molecular signalings and therapeutic applications: Translational potential of deubiquitylating enzyme USP9X as a drug target in cancer treatmentSemantic proximity Read ↗

USP3 : Key deubiquitylation enzyme in human diseasesSemantic proximity Read ↗

TRIM21: a multifaceted regulator in cancerSemantic proximity Read ↗

USP13: Multiple Functions and Target InhibitionSemantic proximity Read ↗

System-wide identification of novel de-ubiquitination targets for USP10 in gastric cancer metastasis through multi-omics screeningSemantic proximity Read ↗

Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cellsSemantic proximity Read ↗

Emerging Potential of Therapeutic Targeting of Ubiquitin-Specific Proteases in the Treatment of CancerSemantic proximity Read ↗

USP19 potentiates autophagic cell death via inhibiting mTOR pathway through deubiquitinating NEK9 in pancreatic cancerSemantic proximity Read ↗

Emerging Role of Ubiquitin-Specific Protease 19 in Oncogenesis and Cancer DevelopmentSemantic proximity Read ↗

Emerging potential of ubiquitin-specific proteases and ubiquitin-specific proteases inhibitors in breast cancer treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.